KNSA vs VCEL: fair value comparison
Kiniksa Pharmaceuticals International, plc and Vericel Corporation · Updated 2026-10-19
VCEL is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, KNSA currently ranks higher by quality score.
| KNSA | VCEL | |
|---|---|---|
| Verdict | Fairly valued | Awaiting full valuation |
| Last price | $78.59 | $40.13 |
| 12-month range | $37.01–$80.92 | $29.34–$48.31 |
| Rank by discount to fair value | #104 of 108 Healthcare | — |
| Rank by quality score | #5 of 301 Healthcare | #7 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: KNSA fair value analysis · VCEL fair value analysis